Oregon's Psilocybin Program Shows Promise, Turns Skeptics Into Believers

For years, the idea of using psilocybin — the active ingredient in 'magic mushrooms' — outside of a tightly controlled medical study was enough to make some researchers clutch their pearls. But a new real-world study from Oregon, the first state to greenlight a non-medical psilocybin program, might just be changing a few minds.

The research, published in JAMA Network Open, tracked nearly 350 people who visited state-licensed psilocybin centers. The big takeaway? Most participants found their experiences genuinely helpful, with over half calling it one of the most meaningful events of their lives. And, perhaps most surprisingly, it appeared remarkably safe.

Only a handful of folks experienced 'serious adverse reactions,' which, if you think about it, is both impressive and slightly terrifying when you consider the substance involved. Dr. Todd Korthuis, who led the study at Oregon Health & Science University, admitted he was initially a skeptic about this whole 'non-medical' approach. The data, however, has made him a convert, calling the results 'very reassuring.'

Not Your Average Clinical Trial

Here's where Oregon's program truly diverges. While much of the psychedelic world is focused on getting FDA approval for substances like psilocybin to treat depression (which might happen next year with synthetic versions), Oregon went a different route. In 2020, voters said, 'Why wait?' and approved a program where adults over 21 can take psilocybin with a trained facilitator, no prescription or doctor's note required. Colorado has since followed suit.

Even other scientists, like Balázs Szigeti from the University of California, San Francisco, were pleasantly surprised. He noted that the rate of problems was similar to what you see with other mental health treatments. 'Good news for psilocybin,' he declared, particularly for a program operating in a regulated business setting. Participants were there for everything from plain old curiosity to mental health support and trauma processing. The average dose was a robust 30 milligrams — a bit higher than what's typically used in clinical trials.

More than half of the study group reported improved mental health symptoms afterward. Szigeti did add the caveat that these findings are tricky to fully interpret without a control group, but the overall boost in well-being was on par with what you'd see from meditation studies. Which, for a single session, is pretty wild.

Safety concerns, when they arose, were mostly mental, not physical. One person had a 'violent reaction' that landed them in the hospital, and another went to the ER for anxiety. Interestingly, all four people with 'serious adverse reactions' were first-timers. The study also noted that three participants reported new thoughts of dying or suicide a week after their session, a number that doubled after three months. A stark reminder that even 'meaningful' experiences can have dark corners.

It's worth noting that this study only captured a fraction of the 20,000+ people who have used Oregon's program. And the demographics were rather specific: mostly white, college-educated, with a third boasting high incomes. Korthuis says this mirrors the general population using the centers, which are mostly clustered around Portland. Albert Garcia-Romeu of Johns Hopkins School of Medicine, however, remains cautious, suggesting the low problem rate might be due to who opted into the study, or how incidents were reported. He's heard plenty of stories about people struggling post-session.

Still, Korthuis is confident his team's future research, tracking a much larger group, will confirm the broader applicability. Because, as he puts it, psychedelics like psilocybin seem to help people explore a whole spectrum of life issues. They might walk in for one reason, and walk out having untangled several. Let that sink in for a moment.